ClinicalTrials.gg

TargetBeta

PTGS2

prostaglandin-endoperoxide synthase 2 · also COX2 · Prostaglandin-endoperoxide synthase family

13 programs in company-led studies act on PTGS2, from 13 companies: 1 in phase 3, 12 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
AspirinruleBayerphase 4844 runningPTGS1ChEMBL
AcetaminophenruleJohnson & Johnsonphase 41363 runningFAAH, PTGS1, TRPV1ChEMBL
IbuprofenrulePfizerphase 41132 runningPTGS1ChEMBL
MeloxicamruleBoehringer Ingelheimphase 4672 running–ChEMBL
EtoricoxibruleOrganonphase 4351 running–ChEMBL
SulfasalazineruleBristol-Myers Squibbphase 471 runningALOX5, PTGS1ChEMBL
dexibuprofenruleAponia Laboratoriesphase 461 runningPTGS1ChEMBL
BenzydamineruleAngelini Pharmaphase 441 runningPTGS1ChEMBL
DipyroneruleHypera Pharmaphase 441 runningPTGS1ChEMBL
CelecoxibruleViatrisphase 4780 running–ChEMBL
dexketoprofenruleMenarini Groupphase 480 runningPTGS1ChEMBL
PiroxicamruleTaisho Pharmaceuticalphase 440 runningPTGS1ChEMBL
FlurbiprofenruleGlaxoSmithKlinephase 3120 runningPTGS1ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.